Cancer-killing virus plus immunotherapy shows promise for hard-to-treat stomach cancers

NCT ID NCT06340711

First seen Apr 25, 2026 · Last updated Jun 09, 2026 · Updated 9 times

Summary

This study tests a new treatment for advanced stomach, esophageal, or gastroesophageal junction cancer that has not responded to standard immunotherapy. The treatment combines a virus (OBP-301) that is injected directly into the tumor with an immunotherapy drug (pembrolizumab) given through an IV. The goal is to see if this combination is safe and effective for people whose tumors are PD-L1-negative or have stopped responding to immunotherapy. About 27 participants will receive up to 5 virus injections and pembrolizumab infusions every 6 weeks for up to 2 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Abramson Cancer Center of the University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Weill Cornell Medicine/NewYork-Presbyterian Hospital

    RECRUITING

    New York, New York, 10065, United States

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.